Advanced Search

Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2008 February;60(1) > Minerva Pediatrica 2008 February;60(1):87-101



A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532

Frequency: Bi-Monthly

ISSN 0026-4946

Online ISSN 1827-1715


Minerva Pediatrica 2008 February;60(1):87-101



Psychopharmacological treatment of non-comorbid and comorbid pervasive developmental disorder and pediatric bipolar disorder

Hamrin V., McDonnell M. A., Moffett J., Durso S.

1 Yale University School of Nursing New Haven, CT, USA
2 S.T.E.P. UP for Kids, Inc. South Shore Psychiatric Service Marshfield, MA, USA
3 Crisis Evaluation Center McLean Hospital Belmont, MA, USA

There is little information on the treatment of comorbid bipolar disorder and pervasive developmental disorder (PDD) in youth. This paper will provide a review of the literature on appropriate psychopharmacological treatment strategies for bipolar disorder and PDD in children and adolescents and make recommendations for psychopharmacological treatment and monitoring of the comorbid presentation of these two disorders. The purpose of this paper is to provide clinicians with evidence-based research findings of treatment strategies used by the experts in the field of pediatric bipolar disorder and PDD. Sources for the study have been published reviews and research articles. Studies addressing the complex treatment issues of comorbid pediatric bipolar disorder and PDD are limited. Research studies have demonstrated improvement in psychiatric functioning of children and adolescents with bipolar disorder and PDDs who took atypical antipsychotics and mood stabilizers. Children with bipolar disorder have benefited the most from the combination of a mood stabilizer plus an antipsychotic. However, there are no studies looking at combined medication treatments for PDD. Children who manifest both disorders could possibly benefit from this combination. While selective serotonin reuptake and tricyclic antidepressants inhibitors have demonstrated improvement in PDD symptoms, they should be used with caution in children who have comorbid bipolar symptoms as they can cause agitation, mania or, in a limited number of cases, serotonin reuptake inhibitors have increased suicidal behavior. More extensive, long-term research is needed to find better treatments to improve quality of life and outcomes in this difficulty to treat population.

language: English


top of page